• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Nephrology and Dialysis >Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
【24h】

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease

机译：托伐普坦治疗扩大的多囊性肝病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m2. Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient’s abdominal fullness began to improve and liver volume, indicating advanced polycystic liver disease (PLD), decreased from 9,750 mL to 8,345 mL after 17 months of tolvaptan treatment, though there was no significant change in kidney volume. This case indicates that tolvaptan may be a therapeutic option for hepatomegaly in patients with symptomatic PLD.
机译：一名44岁的日本人常染色体显性遗传性多囊肾病患者入院接受腹胀评估。她的eGFR为53.7 mL / min / 1.73 m 2 。总肾脏体积为2,614 mL。开始使用托伐普坦（60毫克/天）治疗肾脏受累。患者的腹部饱满度开始改善，肝脏容量增加，表明晚期多囊性肝病（PLD）在托伐普坦治疗17个月后从9,750 mL降至8,345 mL，尽管肾脏体积没有明显变化。该病例表明托伐普坦可能是有症状PLD患者肝肿大的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号